📋 Tender Overview
Scope CSL to build 800 million Melbourne vaccine plant. Biotechnology giant CSL will spend more than 800 million building a new vaccine manufacturing plant at the Melbourne Airport Business Park with operations expected to start in 2026. The plant which will utilise cell-based mass production techniques complements the companys existing vaccine production capabilities which are based on growing vaccines in chicken eggs a technology in use since the 1940s.The new plant will be built by CSLs vaccine subsidiary Seqirus and will produce influenza vaccine as well as the worlds only Q-Fever vaccine and anti-venom for local snakes spiders and marine creatures. That plant received significant investment from the Victorian government with the new plant similarly supported by the state. The Victorian Government is proud to have provided significant support to secure this vital facility in Melbourne which will support hundreds of jobs and many more in the supply chain. The first vaccine supplies will be available in early 2021 depending on the results of clinical trials now underway.
